Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics has two commercial products, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.
|Headquarters||New York, New York|
|Number of employees||51-200 employees|
Top 5 Recent Tweets
|April 20, 2021||BWayynne||@CoronaTurd Yeah was being generous there by limiting it to the time it was under CYDY control. Story for another d… https://t.co/H3b1h589pq|
|April 16, 2021||ProgenicsCB||When you choose Progenics, you can get the most out of your #cordblood. We have always successfully generated a hig… https://t.co/rTZYlEaqe8|
|April 07, 2021||urotoday||The biology of #ProstateCancer metastasis and what #PSMAImaging is teaching us. Presentation by @pienta_brady… https://t.co/i0A8mDZR78|